Gottfried E. Konecny, MD
Whether germline or somatic, patients with recurrent ovarian cancer who harbor BRCA1/2
mutations have shown a unique sensitivity to PARP inhibition. As the field moves forward, optimization of the 3 FDA-approved PARP inhibitors in this setting will come from learning more about the genetic makeup of extreme responders, the features of BRCA
ness, and the underpinnings of adaptive resistance mechanisms, said Gottfried E. Konecny, MD.
... to read the full story